WO2002020573A2 - Nucleotide sequences which code for the gpmb gene - Google Patents

Nucleotide sequences which code for the gpmb gene Download PDF

Info

Publication number
WO2002020573A2
WO2002020573A2 PCT/EP2001/009453 EP0109453W WO0220573A2 WO 2002020573 A2 WO2002020573 A2 WO 2002020573A2 EP 0109453 W EP0109453 W EP 0109453W WO 0220573 A2 WO0220573 A2 WO 0220573A2
Authority
WO
WIPO (PCT)
Prior art keywords
gene
codes
polynucleotide
sequence
amino acid
Prior art date
Application number
PCT/EP2001/009453
Other languages
French (fr)
Other versions
WO2002020573A3 (en
Inventor
Brigitte Bathe
Indra SCHRÖDER
Walter Pfefferle
Original Assignee
Degussa Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10133668A external-priority patent/DE10133668A1/en
Application filed by Degussa Ag filed Critical Degussa Ag
Priority to AU2001295470A priority Critical patent/AU2001295470A1/en
Priority to EP01976088A priority patent/EP1315825A2/en
Publication of WO2002020573A2 publication Critical patent/WO2002020573A2/en
Publication of WO2002020573A3 publication Critical patent/WO2002020573A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/04Alpha- or beta- amino acids
    • C12P13/08Lysine; Diaminopimelic acid; Threonine; Valine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90Isomerases (5.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y504/00Intramolecular transferases (5.4)
    • C12Y504/02Phosphotransferases (phosphomutases) (5.4.2)
    • C12Y504/02001Phosphoglycerate mutase (5.4.2.1)

Definitions

  • the invention provides nucleotide sequences from coryneform bacteria which code for the gpmB gene and a process for the fermentative preparation of amino acids using bacteria in which the gpmB gene is enhanced.
  • L-Amino acids are used in human medicine and in the pharmaceuticals Industry, in the foodstuffs industry and especially in animal nutrition.
  • amino acids are prepared by fermentation from strains of coryneform bacteria, in particular Corynebacterium glutamicum. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as, for example, stirring and supply of oxygen, or the composition of the nutrient media, such as, for example, the sugar concentration during the fermentation, or the working up to the product form by, for example, ion exchange chromatography, or the intrinsic output properties of the microorganism itself.
  • fermentation measures such as, for example, stirring and supply of oxygen
  • the composition of the nutrient media such as, for example, the sugar concentration during the fermentation
  • the working up to the product form by, for example, ion exchange chromatography or the intrinsic output properties of the microorganism itself.
  • Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites or are auxotrophic for metabolites of regulatory importance and produce amino acids are obtained in this manner.
  • the inventors had the object of providing new measures for improved fermentative preparation of amino acids.
  • L-amino acids or amino acids are mentioned in the following, this means one or more amino acids, including their salts, chosen from the group consisting of L- asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L- isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L- histidine, L-lysine, L-tryptophan and L-arginine. L-Lysine is particularly preferred.
  • the invention provides an isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence which codes for the gpmB gene, chosen from the group consisting of
  • polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2,
  • polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70 % to the amino acid sequence of SEQ ID No. 2,
  • polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a) , b) or c) , the polypeptide preferably having the activity of phosphoglycerate mutase II.
  • the invention also provides the above-mentioned polynucleotide, this preferably being a DNA which is capable of replication, comprising:
  • the invention also provides
  • a polynucleotide in particular DNA, which is capable of replication and comprises the nucleotide sequence as shown in SEQ ID No. 1;
  • polynucleotide which codes for a polypeptide which comprises the amino acid sequence as shown in SEQ ID No. 2;
  • a vector containing the polynucleotide according to the invention in particular a shuttle vector or plasmid vector, and
  • coryneform bacteria which contain the vector or in which the gpmB gene is enhanced.
  • the invention also provides polynucleotides which substantially comprise a polynucleotide sequence, which are obtainable by screening by means of hybridization of a corresponding gene library of a coryneform bacterium, which comprises the complete gene or parts thereof, with a probe which comprises the sequence of the polynucleotide according to the invention according to SEQ ID No. 1 or a fragment thereof, and isolation of the polynucleotide sequence mentioned.
  • Polynucleotides which comprise the sequences according to the invention are suitable as hybridization probes for RNA, cDNA, and DNA, in order to isolate, in the full length, nucleic acids or polynucleotides or genes which code for phosphoglycerate mutase II or to isolate those nucleic acids or polynucleotides or genes which have a high similarity of sequence with that of the gpmB gene. They are also suitable for incorporation into so-called “arrays”, “micro arrays” or “DNA chips”, in order to detect and determine the corresponding polynucleotides.
  • Polynucleotides which comprise the sequences according to the invention are furthermore suitable as primers with the aid of which DNA of genes which code for phosphoglycerate mutase II can be prepared by the polymerase chain reaction (PCR) .
  • PCR polymerase chain reaction
  • Such oligonucleotides which serve as probes or primers comprise at least 25, 26, 27, 28, 29 or 30, preferably at least 20, 21, 22, 23 or 24, very particularly preferably at least 15, 16, 17, 18 or 19 successive nucleotides.
  • Oligonucleotides which have a length of at least 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40, or at least 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 nucleotides are also suitable. Oligonucleotides with a length of at least 100, 150, 200, 250 or 300 nucleotides are optionally also suitable.
  • Polynucleotide in general relates to polyribonucleotides and polydeoxyribonucleotides, it being possible for these to be non-modified RNA and DNA or modified RNA and DNA.
  • the polynucleotides according to the invention include a polynucleotide according to SEQ ID No. 1 or a fragment prepared therefrom and also those which are at least 70 % to 80%, preferably at least 81% to 85%, particularly preferably at least 86% to 90%, and very particularly preferably at least 91%, 93%, 95%, 97% or 99% identical to the polynucleotide according to SEQ ID No. 1 or a fragment prepared therefrom.
  • Polypeptides are understood as meaning peptides or proteins which comprise two or more amino acids bonded via peptide bonds.
  • polypeptides according to the invention include a polypeptide according to SEQ ID No. 2, in particular those with the biological activity of phosphoglycerate mutase II and also those which are at least 70% to 80%, preferably at least 81% to 85%, particularly preferably at least 86% to 90%, and very particularly preferably at least 91%, 93%, 95%, 97% or 99% identical to the polypeptide according to SEQ ID No. 2 and have the activity mentioned.
  • the invention furthermore relates to a process for the fermentative preparation of amino acids chosen from the group consisting of L-asparagine, L-threonine, L-serine, L- glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L- methionine, L-isoleucine, L-leucine, L-tyrosine, L- phenylalanine, L-histidine, L-lysine, L-tryptophan and L- arginine using coryneform bacteria which in particular already produce amino acids and in which the nucleotide sequences which code for the gpmB gene are enhanced, in particular over-expressed.
  • amino acids chosen from the group consisting of L-asparagine, L-threonine, L-serine, L- glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L- methionine, L-isole
  • enhancement in this connection describes the increase in the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or using a gene or allele which codes for a corresponding enzyme (protein) having a high activity, and optionally combining these measures.
  • the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on that of the wild-type protein or the activity or concentration of the protein in the starting microorganism.
  • the microorganisms which the present invention provides can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. They can be representatives of coryneform bacteria, in particular of the genus
  • Corynebacterium Of the genus Corynebacterium, there may be mentioned in particular the species Corynebacterium glutamicum, which is known among experts for its ability to produce L-amino acids .
  • Suitable strains of the genus Corynebacterium in particular of the species Corynebacterium glutamicum (C. glutamicum) , are in particular the known wild-type strains
  • the new gpmB gene from C. glutamicum which codes for the enzyme phosphoglycerate mutase II (E.C. 5.4.2.1) has been isolated.
  • E. coli Escherichia coli
  • the setting up of gene libraries is described in generally known textbooks and handbooks. The textbook by Winnacker: Gene und Klone, Amsterdam Einf ⁇ hrung in die Gentechnologie [Genes and Clones, An Introduction to Genetic Engineering] (Verlag Chemie, Weinheim, Germany, 1990), or the handbook by Sambrook et al.: Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989) may be mentioned as an example.
  • a well-known gene library is that of the E. coli K-12 strain W3110 set up in ⁇ vectors by Kohara et al.
  • plasmids such as pBR 322 (Bolivar, Life Sciences, 25, 807-818 (1979)) or p ⁇ C9 (Vieira et al., 1982, Gene, 19:259-268).
  • Suitable hosts are, in particular, those E. coli strains which are restriction- and recombination-defective.
  • An example of these is the strain DH5 mcr, which has been described by Grant et al. (Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649) .
  • the long DNA fragments cloned with the aid of cosmids can in turn be subcloned in the usual vectors suitable for sequencing and then sequenced, as is described e.g. by Sanger et al . (Proceedings of the National Academy of Sciences of the United States of America, 74:5463-5467, 1977).
  • the new DNA sequence of C. glutamicum which codes for the gpmB gene and which, as SEQ ID No. 1, is a constituent of the present invention has been found.
  • the amino acid sequence of the corresponding protein has furthermore been derived from the present DNA sequence by the methods described above.
  • the resulting amino acid sequence of the gpmB gene product is shown in SEQ ID No. 2.
  • Coding DNA sequences which result from SEQ ID No. 1 by the degeneracy of the genetic code are also a constituent of the invention.
  • DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention.
  • Conservative amino acid exchanges such as e.g. exchange of glycine for alanine or of aspartic acid for glutamic acid in proteins, are furthermore known among experts as "sense mutations" which do not lead to a fundamental change in the activity of the protein, i.e. are of neutral function. It is furthermore known that changes on the N and/or C terminus of a protein cannot substantially impair or can even stabilize the function thereof.
  • DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention.
  • DNA sequences which are prepared by the polymerase chain reaction (PCR) using primers which result from SEQ ID No. 1 are a constituent of the invention.
  • PCR polymerase chain reaction
  • Such oligonucleotides typically have a length of at least 15 nucleotides.
  • the hybridization takes place under stringent conditions, that is to say only hybrids in which the probe and target sequence, i. e. the polynucleotides treated with the probe, are at least 70 % identical are formed. It is known that the stringency of the hybridization, including the washing steps, is influenced or determined by varying the buffer composition, the temperature and the salt concentration. The hybridization reaction is preferably carried out under a relatively low stringency compared with the washing steps (Hybaid Hybridisation Guide, Hybaid Limited, Teddington, UK, 1996) .
  • a 5 x SCC buffer at a temperature of approx. 50°C - 68°C, for example, can be employed for the hybridization reaction.
  • Probes can also hybridize here with polynucleotides which are less than 70% identical to the sequence of the probe. Such hybrids are less stable and are removed by washing under stringent conditions. This can be achieved, for example, by lowering the salt concentration to 2 x SSC and optionally subsequently 0.5 x SSC (The DIG System User's Guide for Filter Hybridisation, Boehringer Mannheim, Mannheim, Germany, 1995) a temperature of approx. 50°C - 68°C being established. It is optionally possible to lower the salt concentration to 0.1 x SSC.
  • Polynucleotide fragments which are, for example, at least 70 % or at least 80 % or at least 90 % to 95 % identical to the sequence of the probe employed can be isolated by increasing the hybridization temperature stepwise from 50°C to 68°C in steps of approx. 1 - 2°C. Further instructions on hybridization are obtainable on the market in the form of so-called kits (e. g. DIG Easy Hyb from Roche Diagnostics GmbH, Mannheim, Germany, Catalogue No. 1603558) .
  • kits e. g. DIG Easy Hyb from Roche Diagnostics GmbH, Mannheim, Germany, Catalogue No. 1603558
  • PCR polymerase chain reaction
  • coryneform bacteria produce amino acids in an improved manner after over-expression of the gpmB gene .
  • the number of copies of the corresponding genes can be increased, or the promoter and regulation region or the ribosome linking site upstream of the structural gene can be mutated.
  • Expression cassettes which are incorporated upstream of the structural gene act in the same way.
  • inducible promoters it is additionally possible to increase the expression in the course of fermentative amino acid production.
  • the expression is likewise improved by measures to prolong the life of the m- RNA.
  • the enzyme activity is also increased by preventing the degradation of the enzyme protein.
  • the genes or gene constructs can either be present in plasmids with a varying number of copies, or can be integrated and amplified in the chromosome. Alternatively, an over- expression of the genes in question can furthermore be achieved by changing the composition of the media and the culture procedure.
  • Suitable plasmids are those which are replicated in coryneform bacteria.
  • Numerous known plasmid vectors such as e. g. pZl (Menkel et al., Applied and Environmental Microbiology (1989) 64:549-554), pEKExl (Eikmanns et al., Gene 102:93-98 (1991)) or pHS2-l (Sonnen et al., Gene 107:69-74 (1991)) are based on the cryptic plasmids pHM1519, pBLl or pGAl .
  • plasmid vectors such as e.g. those based on pCG4 (US-A 4,489,160), or pNG2 (Serwold-Davis et al . , FEMS Microbiology Letters 66, 119- 124 (1990)), or pAGl (US-A 5,158,891), can be used in the same manner.
  • Plasmid vectors which are furthermore suitable are also those with the aid of which the process of gene amplification by integration into the chromosome can be used, as has been described, for example, by Reinscheid et co to > M M M n o C ⁇ O C ⁇ O c ⁇
  • L- a ino acids in addition to the enhancement of the gpmB gene, for one or more of the genes chosen from the group consisting of:
  • the term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or using a gene or allele which codes for a corresponding enzyme with a low activity or inactivates the corresponding gene or enzyme (protein) , and optionally combining these measures.
  • the activity or concentration of the corresponding protein is in general reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.
  • the invention also provides the microorganisms prepared according to the invention, and these can be cultured continuously or discontinuously in the batch process (batch culture) or in the fed batch (feed process) or repeated fed batch process (repetitive feed process) for the purpose of production of amino acids.
  • batch culture batch culture
  • feed process fed batch
  • repetitive feed process repeated fed batch process
  • the culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General CO NO r M M o c ⁇ o C ⁇ O C ⁇
  • Suitable substances having a selective action can be added to the medium to maintain the stability of plasmids.
  • oxygen or oxygen-containing gas mixtures such as e.g. air, are introduced into the culture.
  • the temperature of the culture is usually 20°C to 45°C, and preferably 25°C to 40°C. Culturing is continued until a maximum of the desired product has formed. This target is usually reached within 10 hours to 160 hours.
  • the process according to the invention is used for fermentative preparation of amino acids.
  • DSMZ German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany
  • composition of the usual nutrient media such as LB or TY medium, can also be found in the handbook by Sambrook et al.
  • the cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany Product Description BamHI, Code no. 27-0868-04) .
  • BamHI Amersham Pharmacia, Freiburg, Germany Product Description BamHI, Code no. 27-0868-04
  • the cosmid DNA treated in this manner was mixed with the treated ATCC13032 DNA and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA-
  • Ligase Code no. 27-0870-04
  • the ligation mixture was then packed in phages with the aid of Gigapack II XL Packing Extract (Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217) .
  • Gigapack II XL Packing Extract Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217
  • the cells were taken up in 10 mM MgS0 4 and mixed with an aliquot of the phage suspension.
  • the infection and titering of the cosmid library were carried out as described by Sambrook et al . (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor) , the cells being plated out on LB agar (Lennox, 1955, Virology, 1:190) with 100 mg/1 ampicillin. After incubation overnight at 37°C, recombinant individual clones were selected.
  • the cosmid DNA of an individual colony was isolated with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and partly cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, Product Description Sau3AI, Product No. 27-0913-02) .
  • the DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product Description SAP, Product No. 1758250) .
  • the cosmid fragments in the size range of 1500 to 2000 bp were isolated with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany) .
  • the DNA of the sequencing vector pZero-1 obtained from Invitrogen (Groningen, Holland, Product Description Zero Background Cloning Kit, Product No. K2500-01) , was cleaved with the restriction enzy BamHI (Amersham Pharmacia, Freiburg, Germany, Product Description BamHI, Product No. 27-0868-04) .
  • the ligation of the cosmid fragments in the sequencing vector pZero-1 was carried out as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor) , the DNA mixture being incubated overnight with T4 ligase (Pharmacia Biotech, Freiburg, Germany) . This ligation mixture was then electroporated (Tauch et al.
  • the plasmid preparation of the recombinant clones was carried out with the Biorobot 9600 (Product No. 900200, Qiagen, Hilden Germany) .
  • the sequencing was carried out by the dideoxy chain-stopping method of Sanger et al. (1977, Proceedings of the National Academy of Sciences U.S.A.,
  • the raw sequence data obtained were then processed using the Staden program package (1986, Nucleic Acids Research, 14:217:231) version 97-0.
  • the individual sequences of the pZerol derivatives were assembled to a continuous contig.
  • the computer-assisted coding region analysis was prepared with the XNIP program (Staden, 1986, Nucleic Acids Research, 14:217-231).
  • the resulting nucleotide sequence is shown in SEQ ID No. 1. Analysis of the nucleotide sequence showed an open reading frame of 705 base pairs, which was called the gpmB gene.
  • the gpmB gene codes for a protein of 235 amino acids.
  • chromosomal DNA was isolated by the method of Eikmanns et al. (Microbiology 140: 1817-1828 (1994) ) .
  • the following oligonucleotides were chosen for the polymerase chain reaction (see SEQ ID No. 3 and SEQ ID No. 4) :
  • gpmBexl 5 " ca ggtacc tgg eta cga gga cga tta ag 3 gpmBex2 : 5' tg tctaga aag cat gcg gag gaa tea ac 3"
  • the primers shown were synthesized by MWG-Biotech AG (Ebersberg, Germany) and the PCR reaction was carried out by the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press) with Pwo-Polymerase from Roche Diagnostics GmbH (Mannheim, Germany) . With the aid of the polymerase chain reaction, the primers allow amplification of a DNA fragment 827 bp in size, which carries the gpmB gene.
  • the primer gpmBexl contains the sequence for the cleavage site of the restriction endonuclease Kpnl, and the primer gpmBex2 the cleavage site of the restriction endonuclease Xbal, which are marked by underlining in the nucleotide sequence shown above.
  • the gpmB fragment 827 bp in size was cleaved with the restriction endonucleases Kpnl and Xbal and then isolated from the agarose gel with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany) .
  • the E. coli - C. glutamicum shuttle vector pEC-XK99E was constructed according to the prior art.
  • the vector contains the replication region rep of the plasmid pGAl including the replication effector per (US-A-5, 175, 108; Nesvera et al., Journal of Bacteriology 179, 1525-1532 (1997)), the kanamycin resistance gene aph(3')-Ha from Escherichia coli (Beck et al .
  • the trc promoter can be induced by addition of the lactose derivative IPTG (isopropyl ?-D-thiogalactopyranoside) .
  • the E. coli - C. glutamicum shuttle vector pEC-XK99E constructed was transferred into C. glutamicum DSM5715 by means of electroporation (Liebl et al., 1989, FEMS Microbiology Letters, 53:299-303). Selection of the transfor ants took place on LBHIS agar comprising 18.5 g/l brain-heart infusion broth, 0.5 M sorbitol, 5 g/l Bacto- tryptone, 2.5 g/l Bacto-yeast extract, 5 g/l NaCl and 18 g/l Bacto-agar, which had been supplemented with 25 mg/1 kanamycin. Incubation was carried out for 2 days at 33°C.
  • Plasmid DNA was isolated from a transformant by conventional methods (Peters-Wendisch et al., 1998, Microbiology, 144, 915 - 927), cleaved with the restriction endonuclease Hindlll, and the plasmid was checked by subsequent agarose gel electrophoresis.
  • the plasmid construct obtained in this way was called pEC- XK99E (figure 1) .
  • CD ro ⁇ 3 -J 3 ⁇ d CD •*» ⁇ -J s: s: a rt cn hj 0 tO li Cfl 3 ⁇ ⁇
  • the strain DSM5715 was transformed with the plasmid pEC- XK99EgpmBalex using the electroporation method described by Liebl et al., (FEMS Microbiology Letters, 53:299-303 (1989) ) . Selection of the transformants took place on LBHIS agar comprising 18.5 g/l brain-heart infusion broth, 0.5 M sorbitol, 5 g/l Bacto-tryptone, 2.5 g/l Bacto-yeast extract, 5 g/l NaCl and 18 g/l Bacto-agar, which had been supplemented with 25 mg/1 kanamycin. Incubation was carried out for 2 days at 33°C.
  • Plasmid DNA was isolated from a transformant by conventional methods (Peters-Wendisch et al., 1998, Microbiology, 144, 915 - 927), cleaved with the restriction endonucleases Xbal and Kpnl, and the plasmid was checked by subsequent agarose gel electrophoresis. The strain obtained was called DSM5715/pEC-XK99EgpmBalex.
  • the C. glutamicum strain DSM5715/pEC-XK99EgpmBalex obtained in example 4 was cultured in a nutrient medium suitable for the production of lysine and the lysine content in the culture supernatant was determined.
  • the strain was first incubated on an agar plate with the corresponding antibiotic (brain-heart agar with kanamycin (25 mg/1)) for 24 hours at 33°C.
  • a preculture was seeded (10 ml medium in a 100 ml conical flask) .
  • the complete medium Cglll was used as the medium for the preculture.
  • Kanamycin 25 mg/1 was added to this.
  • the preculture was incubated for 16 hours at 33°C at 240 rpm on a shaking machine.
  • a main culture was seeded from this preculture such that the initial OD (660nm) of the main culture was 0.1.
  • Medium MM was used for the main culture.
  • MOPS morpholinopropanesulfonic acid
  • the CSL, MOPS and the salt solution were brought to pH 7 with aqueous ammonia and autoclaved.
  • the sterile substrate and vitamin solutions were then added, as well as the CaC0 3 autoclaved in the dry state.
  • Culturing is carried out in a 10 ml volume in a 100 ml conical flask with baffles. Kanamycin (25 mg/1) and IPTG (lmM/1) was added. Culturing was carried out at 33°C and 80% atmospheric humidity.
  • the OD was determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Kunststoff) .
  • the amount of lysine formed was determined with an amino acid analyzer from Eppendorf- BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivation with ninhydrin detection.
  • FIG. 1 Map of the plasmid pEC-XK99E
  • Kan Kanamycin resistance gene aph(3 , )-IIa from Escherichia coli

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to an isolated polynucleotide comprising a polynucleotide sequence chosen from the group consisting of a) polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2, b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70% to the amino acid sequence of SEQ ID No. 2, c) polynucleotide which is complementary to the polynucleotides of a) or b), and d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c), and a process for the fermentative preparation of L-amino acids using coryneform bacteria in which at least the gpmB gene is present in enhanced form, and the use of polynucleotides which comprise the sequences according to the invention as hybridization probes.

Description

Nucleotide sequences which code for -the gpmB gene
Field of the Invention
The invention provides nucleotide sequences from coryneform bacteria which code for the gpmB gene and a process for the fermentative preparation of amino acids using bacteria in which the gpmB gene is enhanced.
Prior Art
L-Amino acids are used in human medicine and in the pharmaceuticals Industry, in the foodstuffs industry and especially in animal nutrition.
It is known that amino acids are prepared by fermentation from strains of coryneform bacteria, in particular Corynebacterium glutamicum. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as, for example, stirring and supply of oxygen, or the composition of the nutrient media, such as, for example, the sugar concentration during the fermentation, or the working up to the product form by, for example, ion exchange chromatography, or the intrinsic output properties of the microorganism itself.
Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites or are auxotrophic for metabolites of regulatory importance and produce amino acids are obtained in this manner.
Methods of the recombinant DNA technique have also been employed for some years for improving the strain of
Corynebacterium strains which produce L-amino acid, by amplifying individual amino acid biosynthesis genes and investigating the effect on the amino acid production.
Object of the Invention
The inventors had the object of providing new measures for improved fermentative preparation of amino acids.
Summary of the Invention
Where L-amino acids or amino acids are mentioned in the following, this means one or more amino acids, including their salts, chosen from the group consisting of L- asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L- isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L- histidine, L-lysine, L-tryptophan and L-arginine. L-Lysine is particularly preferred.
The invention provides an isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence which codes for the gpmB gene, chosen from the group consisting of
a) polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2,
b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70 % to the amino acid sequence of SEQ ID No. 2,
c) polynucleotide which is complementary to the polynucleotides of a) or b) , and
d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a) , b) or c) , the polypeptide preferably having the activity of phosphoglycerate mutase II.
The invention also provides the above-mentioned polynucleotide, this preferably being a DNA which is capable of replication, comprising:
(i) the nucleotide sequence shown in SEQ ID No. 1, or
(ii) at least one sequence which corresponds to sequence (i) within the range of the degeneration of the genetic code, or
(iii) at least one sequence which hybridizes with the sequence complementary to sequence (i) or (ii) , and optionally
(iv) sense mutations of neutral function in (i) .
The invention also provides
a polynucleotide, in particular DNA, which is capable of replication and comprises the nucleotide sequence as shown in SEQ ID No. 1;
a polynucleotide which codes for a polypeptide which comprises the amino acid sequence as shown in SEQ ID No. 2;
a vector containing the polynucleotide according to the invention, in particular a shuttle vector or plasmid vector, and
coryneform bacteria which contain the vector or in which the gpmB gene is enhanced.
The invention also provides polynucleotides which substantially comprise a polynucleotide sequence, which are obtainable by screening by means of hybridization of a corresponding gene library of a coryneform bacterium, which comprises the complete gene or parts thereof, with a probe which comprises the sequence of the polynucleotide according to the invention according to SEQ ID No. 1 or a fragment thereof, and isolation of the polynucleotide sequence mentioned.
Detailed Description of the Invention
Polynucleotides which comprise the sequences according to the invention are suitable as hybridization probes for RNA, cDNA, and DNA, in order to isolate, in the full length, nucleic acids or polynucleotides or genes which code for phosphoglycerate mutase II or to isolate those nucleic acids or polynucleotides or genes which have a high similarity of sequence with that of the gpmB gene. They are also suitable for incorporation into so-called "arrays", "micro arrays" or "DNA chips", in order to detect and determine the corresponding polynucleotides.
Polynucleotides which comprise the sequences according to the invention are furthermore suitable as primers with the aid of which DNA of genes which code for phosphoglycerate mutase II can be prepared by the polymerase chain reaction (PCR) .
Such oligonucleotides which serve as probes or primers comprise at least 25, 26, 27, 28, 29 or 30, preferably at least 20, 21, 22, 23 or 24, very particularly preferably at least 15, 16, 17, 18 or 19 successive nucleotides.
Oligonucleotides which have a length of at least 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40, or at least 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 nucleotides are also suitable. Oligonucleotides with a length of at least 100, 150, 200, 250 or 300 nucleotides are optionally also suitable.
"Isolated" means separated out of its natural environment. "Polynucleotide" in general relates to polyribonucleotides and polydeoxyribonucleotides, it being possible for these to be non-modified RNA and DNA or modified RNA and DNA.
The polynucleotides according to the invention include a polynucleotide according to SEQ ID No. 1 or a fragment prepared therefrom and also those which are at least 70 % to 80%, preferably at least 81% to 85%, particularly preferably at least 86% to 90%, and very particularly preferably at least 91%, 93%, 95%, 97% or 99% identical to the polynucleotide according to SEQ ID No. 1 or a fragment prepared therefrom.
"Polypeptides" are understood as meaning peptides or proteins which comprise two or more amino acids bonded via peptide bonds.
The polypeptides according to the invention include a polypeptide according to SEQ ID No. 2, in particular those with the biological activity of phosphoglycerate mutase II and also those which are at least 70% to 80%, preferably at least 81% to 85%, particularly preferably at least 86% to 90%, and very particularly preferably at least 91%, 93%, 95%, 97% or 99% identical to the polypeptide according to SEQ ID No. 2 and have the activity mentioned.
The invention furthermore relates to a process for the fermentative preparation of amino acids chosen from the group consisting of L-asparagine, L-threonine, L-serine, L- glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L- methionine, L-isoleucine, L-leucine, L-tyrosine, L- phenylalanine, L-histidine, L-lysine, L-tryptophan and L- arginine using coryneform bacteria which in particular already produce amino acids and in which the nucleotide sequences which code for the gpmB gene are enhanced, in particular over-expressed. The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or using a gene or allele which codes for a corresponding enzyme (protein) having a high activity, and optionally combining these measures.
By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on that of the wild-type protein or the activity or concentration of the protein in the starting microorganism.
The microorganisms which the present invention provides can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. They can be representatives of coryneform bacteria, in particular of the genus
Corynebacterium. Of the genus Corynebacterium, there may be mentioned in particular the species Corynebacterium glutamicum, which is known among experts for its ability to produce L-amino acids .
Suitable strains of the genus Corynebacterium, in particular of the species Corynebacterium glutamicum (C. glutamicum) , are in particular the known wild-type strains
Corynebacterium glutamicum ATCC13032 Corynebacterium acetoglutamicum ATCC15806 Corynebacterium acetoacidophilum ATCC 13870
Corynebacterium thermoaminogenes FERM BP-1539 Corynebacterium melassecola ATCC17965 Brevibacterium flavum ATCC14067 Brevibacterium lactofermentum ATCC13869 and Brevibacterium devaricatum ATCC14020
and L-amino acid-producing mutants or strains prepared therefrom.
The new gpmB gene from C. glutamicum which codes for the enzyme phosphoglycerate mutase II (E.C. 5.4.2.1) has been isolated.
To isolate the gpmB gene or also other genes of C. glutamicum, a gene library of this microorganism is first set up in Escherichia coli (E. coli) . The setting up of gene libraries is described in generally known textbooks and handbooks. The textbook by Winnacker: Gene und Klone, Eine Einfϋhrung in die Gentechnologie [Genes and Clones, An Introduction to Genetic Engineering] (Verlag Chemie, Weinheim, Germany, 1990), or the handbook by Sambrook et al.: Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989) may be mentioned as an example. A well-known gene library is that of the E. coli K-12 strain W3110 set up in λ vectors by Kohara et al. (Cell 50, 495 -508 (1987)). Bathe et al. (Molecular and General Genetics, 252:255-265, 1996) describe a gene library of C. glutamicum ATCC13032, which was set up with the aid of the cosmid vector SuperCos I (Wahl et al . , 1987, Proceedings of the National Academy of Sciences USA, 84:2160-2164) in the E. coli K-12 strain NM554 (Raleigh et al., 1988, Nucleic Acids Research 16:1563-1575).
Bδrmann et al. (Molecular Microbiology 6(3), 317-326)) (1992)) in turn describe a gene library of C. glutamicum ATCC13032 using the cosmid pHC79 (Hohn and Collins, Gene 11, 291-298 (1980) ) .
To prepare a gene library of C. glutamicum in E. coli it is also possible to use plasmids such as pBR 322 (Bolivar, Life Sciences, 25, 807-818 (1979)) or pϋC9 (Vieira et al., 1982, Gene, 19:259-268). Suitable hosts are, in particular, those E. coli strains which are restriction- and recombination-defective. An example of these is the strain DH5 mcr, which has been described by Grant et al. (Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649) . The long DNA fragments cloned with the aid of cosmids can in turn be subcloned in the usual vectors suitable for sequencing and then sequenced, as is described e.g. by Sanger et al . (Proceedings of the National Academy of Sciences of the United States of America, 74:5463-5467, 1977).
The new DNA sequence of C. glutamicum which codes for the gpmB gene and which, as SEQ ID No. 1, is a constituent of the present invention has been found. The amino acid sequence of the corresponding protein has furthermore been derived from the present DNA sequence by the methods described above. The resulting amino acid sequence of the gpmB gene product is shown in SEQ ID No. 2.
Coding DNA sequences which result from SEQ ID No. 1 by the degeneracy of the genetic code are also a constituent of the invention. In the same way, DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention. Conservative amino acid exchanges, such as e.g. exchange of glycine for alanine or of aspartic acid for glutamic acid in proteins, are furthermore known among experts as "sense mutations" which do not lead to a fundamental change in the activity of the protein, i.e. are of neutral function. It is furthermore known that changes on the N and/or C terminus of a protein cannot substantially impair or can even stabilize the function thereof. Information in this context can be found by the expert, inter alia, in Ben-Bassat et al. (Journal of Bacteriology 169:751-757 (1987)), in 0' Regan et al. (Gene 77:237-247 (1994)), in Sahin-Toth et al. (Protein Sciences 3:240-247 (1994)), in Hochuli et al. (Bio/Technology 6:1321-1325 (1988)) and in known textbooks of genetics and molecular biology. Amino acid sequences which result in a corresponding manner from SEQ ID No. 2 are also a constituent of the invention.
In the same way, DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention. Finally, DNA sequences which are prepared by the polymerase chain reaction (PCR) using primers which result from SEQ ID No. 1 are a constituent of the invention. Such oligonucleotides typically have a length of at least 15 nucleotides.
Instructions for identifying DNA sequences by means of hybridization can be found by the expert, inter alia, in the handbook "The DIG System Users Guide for Filter Hybridization" from Boehringer Mannheim GmbH (Mannheim,
Germany, 1993) and in Liebl et al. (International Journal of Systematic Bacteriology (1991) 41: 255-260). The hybridization takes place under stringent conditions, that is to say only hybrids in which the probe and target sequence, i. e. the polynucleotides treated with the probe, are at least 70 % identical are formed. It is known that the stringency of the hybridization, including the washing steps, is influenced or determined by varying the buffer composition, the temperature and the salt concentration. The hybridization reaction is preferably carried out under a relatively low stringency compared with the washing steps (Hybaid Hybridisation Guide, Hybaid Limited, Teddington, UK, 1996) .
A 5 x SCC buffer at a temperature of approx. 50°C - 68°C, for example, can be employed for the hybridization reaction. Probes can also hybridize here with polynucleotides which are less than 70% identical to the sequence of the probe. Such hybrids are less stable and are removed by washing under stringent conditions. This can be achieved, for example, by lowering the salt concentration to 2 x SSC and optionally subsequently 0.5 x SSC (The DIG System User's Guide for Filter Hybridisation, Boehringer Mannheim, Mannheim, Germany, 1995) a temperature of approx. 50°C - 68°C being established. It is optionally possible to lower the salt concentration to 0.1 x SSC. Polynucleotide fragments which are, for example, at least 70 % or at least 80 % or at least 90 % to 95 % identical to the sequence of the probe employed can be isolated by increasing the hybridization temperature stepwise from 50°C to 68°C in steps of approx. 1 - 2°C. Further instructions on hybridization are obtainable on the market in the form of so-called kits (e. g. DIG Easy Hyb from Roche Diagnostics GmbH, Mannheim, Germany, Catalogue No. 1603558) .
Instructions for amplification of DNA sequences with the aid of the polymerase chain reaction (PCR) can be found by the expert, inter alia, in the handbook by Gait: Oligonucleotide Synthesis: A Practical Approach (IRL Press, Oxford, UK, 1984) and in Newton and Graham: PCR (Spektrum Akademischer Verlag, Heidelberg, Germany, 1994).
It has been found that coryneform bacteria produce amino acids in an improved manner after over-expression of the gpmB gene .
To achieve an over-expression, the number of copies of the corresponding genes can be increased, or the promoter and regulation region or the ribosome linking site upstream of the structural gene can be mutated. Expression cassettes which are incorporated upstream of the structural gene act in the same way. By inducible promoters, it is additionally possible to increase the expression in the course of fermentative amino acid production. The expression is likewise improved by measures to prolong the life of the m- RNA. Furthermore, the enzyme activity is also increased by preventing the degradation of the enzyme protein. The genes or gene constructs can either be present in plasmids with a varying number of copies, or can be integrated and amplified in the chromosome. Alternatively, an over- expression of the genes in question can furthermore be achieved by changing the composition of the media and the culture procedure.
Instructions in this context can be found by the expert, inter alia, in Martin et al. (Bio/Technology 5, 137-146 (1987)), in Guerro et al. (Gene 138, 35-41 (1994)), Tsuchiya and Morinaga (Bio/Technology 6, 428-430 (1988)), in Eikmanns et al. (Gene 102, 93-98 (1991)), in EP 427,869, in US 4,601,893, in Schwarzer and Pilhler (Bio/Technology 9, 84-87 (1991), in Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)), in LaBarre et al. (Journal of Bacteriology 175, 1001-1007 (1993)), in WO 96/15246, in Malumbres et al. (Gene 134, 15 -24 (1993)), in JP-A-10-229891, in Jensen and Hammer (Biotechnology and Bioengineering 58, 191-195 (1998)), in Makrides (Microbiolgical Reviews 60:512-538 (1996)) and in known textbooks of genetics and molecular biology.
By way of example, for enhancement the gpmB gene according to the invention was over-expressed with the aid of episomal plasmids . Suitable plasmids are those which are replicated in coryneform bacteria. Numerous known plasmid vectors, such as e. g. pZl (Menkel et al., Applied and Environmental Microbiology (1989) 64:549-554), pEKExl (Eikmanns et al., Gene 102:93-98 (1991)) or pHS2-l (Sonnen et al., Gene 107:69-74 (1991)) are based on the cryptic plasmids pHM1519, pBLl or pGAl . Other plasmid vectors, such as e.g. those based on pCG4 (US-A 4,489,160), or pNG2 (Serwold-Davis et al . , FEMS Microbiology Letters 66, 119- 124 (1990)), or pAGl (US-A 5,158,891), can be used in the same manner.
Plasmid vectors which are furthermore suitable are also those with the aid of which the process of gene amplification by integration into the chromosome can be used, as has been described, for example, by Reinscheid et co to > M M M n o Cπ O Cπ O cπ
φ H9 cQ O rt sQ 3 tr1 H M CD ω CD rt s Φ rt P- ≤ _ CD s Ω M Ό -J _ φ Ω Ό o _ CD
3 3- Φ *o 31 M o 1 3 Φ M M M H H- ? ϋ 3 tr CΛ M o hi CTl n CO. X O M Ό M M
3J β 3 rt Φ ^ i-i CD CD 3 CO tø o • CD Ω CD CD rt P- Ό • M O O
^ ?d O CD M CD φ O •
CD ω Φ P- Ω Φ 3 CD Cfl Ω 1 00 00 3 li 3 3 O Ω li φ 3 • • ) ^^ 00 P- O ϋ UO
3 *«* O Ό 0 P- Q- rt H CO KΩ 00 . — . Cfl O Ό CO tr CD Ω P- • M CO Ό — 3 0 *> ^^
Ω 3 Φ M Φ 3 O Ji- — ^^ > Hi tr M Hi rt rt M β 3 M UO " — M ^ P- 3 - — >
Φ Hi CD 3 ^ 3 O P- rt Cfl ^J — — Ό O H- Φ O tr Ω rt ID M sQ CTi 1 UO — φ α — - •Ό"
3 O M rt Cfl N rt Z Cfl Ό li o H Φ o UO CD Φ 3 *• "«« σ *o
Φ li M 0 p- * ; CD P- o ^-^ CD M 3 M 3 3 Φ M li 3 00 O " — β <1 H Hi M
3 ^ Cfl Cfl 3 Ω O 0 M 3 α H- CD 0 tr CD rt rt 1 nj - — S Ό rt 3 0 P- rt rt Φ Φ P- 3 Ω <! ^ α d Φ rt •< rt φ CD ω 00 O ^ E CΛ Ω hi φ
3J l-i Cfl α -> O Φ SD 3 α H- ■< P- CO P- CD j P- 1^ . . ' M 3 rt rt α
O Φ Φ Ό o Cfl Ό li ^ m p. 0 cn O P- 3 M o o tr -<• ^~. Ό 00 no1 O O tr a
Hi cQ - Hi O P- P- 3 ^-* CD Ω s 3 <Tι Ω 3 hi Cfl • β M Φ CΛ Q 3 O rt li P- β D
Ό β O Hi rt rt Φ — c CD H- o tr Φ H O σ tr H o O co 3 rh H M Cfl CD O Cfl Φ • o 3 Ω CD CD: 0- rt 3 ιQ 2 ω β S tr M P- s: M α tT Φ CD Ό 3 rt 3 <j t li H Hi ■-3 tr M CD << Φ I 3 1 3 tr 3 P-
Φ Ό rt 3- CD tr Φ CD O Φ > CD O φ ~J φ t o Φ υD M rt > CD ι-3 o ,-— P- Φ Ω M
0) O 0) Ό φ 3 <: Hi 3 Hi Φ 3 tr Cn H φ rt 00 tr 3 hi CΛ o Ω rt CD 3 vQ H rt M tT rt rt rt 0- H- α CTi li sQ (Tι O ) Φ cπ ,— . P- • t tr rt <
Ό 03 ■<: Φ Φ •0 CD tr rt Φ o φ 1 φ 3 CD Φ Hi O hi ,-,. <xi Ό 3 0 P- P-
3 rt hj SD 3 Φ - H CD CΛ M Cfl -J rt φ P- 3 J^ M J^ M li P^! o iQ Ω 0- o tj P- t$ Ω O hj Ω Φ rt M - O Ω Cn rt 3 φ O ω • • D 00 O O M 3 M CD 3 o
O hj * CO rt Φ CD - P- • H- iQ li SO CD tr Φ CD Cπ 3 ~J UO 3 O β 3 3 ιQ 3 O O P- P- P- sQ Φ O * H- M o 0 rt 3 Ω CO 0- d-*. φ 3 Φ rt rt O 3
Φ rt M Cfl Ω <i Φ 3 . — . 3 tr -— . • Hi 0 Φ rt J-» Cfl O ιQ o rt CD li tr hi φ
3 O Φ Φ » β P- CD 3 li o •^ CD CD Φ M Φ 1 o ^ CD tr 3 φ φ 3
Φ Hi P- -* M 3 3 φ Φ M M 3 3 α ( ) . — ^ o o σ J-> hi cπ CO CD p- Ό CD rt
3 O CD rt cn O S ^ l£> > Hi • Φ M P- to • — ' C| Ω . — M Ω M Ω 3 CD
IT1 Cfl 0 Hi H Ό CU P- β ιQ ω . — . ^ Ό • > O M φ O O ω • β P- o i M
O 1 *% Hi CD ιQ 3 M O DO C Hi — Ό Ω iQ CD CO M li β hi Ω . 3 Ω 3 M
3 CD rt tr H Φ rt C S H- H- 0 ~ — M o M 3 CO O ^-, 3 Ό hi Ό U CD Ό P- S
Φ 3 P- CD 3- P- rt O (Q P- fl H- O O li • H- 3 β •O -J ιQ M CD o 3 O CD: Od rt M hti P-
P- 3 3 Φ O P- β β 3 Ω rt Φ t_j- rt M 1 •< υo hi ta CD li Hi P- <τ) Φ φ P- Ω
O 3 P- Cfl Ω O Φ ιQ li li ι-3 Φ Φ s β CD P- CO UO
CD 3 O Hi *~ M CO ® M CD Φ o O rt Ω li hj O •<: β Cfl Φ O Φ Ω φ ιQ 3 O P- Φ CD O
0- O P- 3 M Hi rt Cfl O tr Ω tr CD rt CD CD P- P- ) -J — w rt ϋ ^^ φ O P- m CO 3 rt tr
3 CD P- rt rt CD O P- rt O H- tr 3 3 tr 3 rt Ω Φ — • O rt β Hi O Φ Φ P- cQ P- P-
O O P- CD n tr hi l-i O n 3 O 3 O Ό o P- β Q. • • • -* 3 3 rt Ω tr CD Φ O o i-i P- rt Ω μ. Φ 3 CD σ M o M M a. O 3 J-> CD j-j- td -> tr M 3 3 M φ P- P- Ω Cfl O rt • P- H- O M O Φ fl M 3 P- 3 Cπ O M P- CD 3 Φ tr Φ O cn 0 P- <! 3- 3 3 iQ O iQ 3 σ CD tr M M • o S M o o O ιQ iQ 3 CD cn φ Φ CD H- iQ ^ Hi <! P- •<: φ o S . l— 1 M CD • M < CO P- Hi ^
Φ Φ Ω H Ω rt Ω ^ σ o P- CO rt 1 M 3 o CL ^ O Φ ct Q
3 P- rt xi H- Ό 1 Ό O H- CD f ■< li H Ω tr Ό -l n ^-^ O <l vQ P- ιQ Ω rt -
Φ 3 O Ό α Φ li 3 O M -J VD 0 α 0 φ M c P- P- O Q >< rt ^-^ Ω tr o
CO o rt Ix! O rt 3 ι-3 3 Φ 3 3 CD Λ β ri- Ω O Φ O rt M Φ
U> r+ hj Ω tr Ό CD tr 3 Cfl L_l- Cfl Ti Ω li li CD 3 3 M li o S O
3" rt : s: l-i β P- σ Φ M co H- Φ Ω β rt 3 - — tr 3 M -> Φ -» O 3 tr M
CD α Φ Ω CD Φ Ω 3 rt O ϋi φ 3 M U3 hi P- hi CD P- Φ o M
Ω P- 0) M ■ Cfl rt CO rt σi O^i H rt P- CD CD
"^ α o β M Φ O SI M -J CD Ω CL
Cfl P- 3 cn
Ω rt ιQ 3 φ 3 Φ 1 cr CD tr rt 3 li 3 3 tr H J^. 00 li CD 1 1
O P- Ό α ** O CD φ i 1 CO D M Φ P- CO < } O Φ -* cπ Φ M P- rt M i O 3 o O 3 rt CD CO M Tl Ω 0 Hi Φ •d Hi Hi 3 "^ 1 M 3 tr CO α 3 d o Hi 3 3 O [SJ tr 3 φ Ω tt) P- a -J •<: H M
P- Hi Φ O Cfl M -J li rt CD Φ Cfl Λ σi o Hi CD CO
3 rt Hi N3 o Φ Hi O li O CΛ rt rt > o M O M Q O O o 'ω rt O Φ li CO hi 1 H •
Hi H α •^
to the biosynthesis pathway, chosen from the group consisting of
• the dapA gene which codes for dihydrodipicolinate synthase (EP-B 0 197 335),
• the gap gene which codes for glyceraldehyde 3-phosphate dehydrogenase (Eikmanns (1992) , Journal of Bacteriology 174:6076-6086) ,
• the tpi gene which codes for triose phosphate isomerase
(Eikmanns (1992), Journal of Bacteriology 174:6076- 6086) ,
• the pgk gene which codes for 3-phosphoglycerate kinase (Eikmanns (1992), Journal of Bacteriology 174:6076- 6086) ,
• the zwf gene which codes for glucose 6-phosphate dehydrogenase (JP-A-09224661) ,
• the pyc gene which codes for pyruvate carboxylase (DE-A 198 31 609) ,
• the mqo gene which codes for alate-quinone oxidoreductase (Molenaar et al., European Journal of Biochemistry 254, 395-403 (1998)),
• the lysC gene which codes for a feed-back resistant aspartate kinase (Accession No.P26512; EP-B-0387527 ; EP- A-0699759) ,
• the lysE gene which codes for lysine export (DE-A-195 48 222),
• the horn gene which codes for homoserine dehydrogenase (EP-A 0131171) ,
• the ilvA gene which codes for threonine dehydratase
(Mδckel et al . , Journal of Bacteriology (1992) 8065- 8072)), or the ilvA(Fbr) allele which codes for a "feed back resistant" threonine dehydratase Mδckel et al., (1994) Molecular Microbiology 13: 833-842),
• the ilvBN gene which codes for acetohydroxy-acid synthase (EP-B 0356739),
• the ilvD gene which codes for dihydroxy-acid dehydratase
(Sahm and Eggeling (1999) Applied and Environmental Microbiology 65: 1973-1979),
• the zwal gene which codes for the Zwal protein (DE: 19959328.0, DSM 13115)
can be enhanced, in particular over-expressed.
It may furthermore be advantageous for the production of L- a ino acids, in addition to the enhancement of the gpmB gene, for one or more of the genes chosen from the group consisting of:
• the pck gene which codes for phosphoenol pyruvate carboxykinase (DE 199 50 409.1; DSM 13047),
• the pgi gene which codes for glucose 6-phosphate isomerase (US 09/396,478; DSM 12969),
• the poxB gene which codes for pyruvate oxidase (DE: 1995 1975.7; DSM 13114) ,
• the zwa2 gene which codes for the Zwa2 protein (DE: 19959327.2, DSM 13113)
to be attenuated, in particular for the expression thereof to be reduced.
The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or using a gene or allele which codes for a corresponding enzyme with a low activity or inactivates the corresponding gene or enzyme (protein) , and optionally combining these measures.
By attenuation measures, the activity or concentration of the corresponding protein is in general reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.
In addition to over-expression of it gpmB gene it may furthermore be advantageous for the production of amino acids to eliminate undesirable side reactions (Nakayama: "Breeding of Amino Acids Producing Micro-organisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).
The invention also provides the microorganisms prepared according to the invention, and these can be cultured continuously or discontinuously in the batch process (batch culture) or in the fed batch (feed process) or repeated fed batch process (repetitive feed process) for the purpose of production of amino acids. A summary of known culture methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einfϋhrung in die Bioverfahrenstechnik [Bioprocess Technology 1. Introduction to Bioprocess Technology (Gustav Fischer Verlag, Stuttgart, 1991) ) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen [Bioreactors and Peripheral Equipment] (Viehweg Verlag, Braunschweig/Wiesbaden, (1994)).
The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General CO NO r M M o cπ o Cπ O Cπ
P- n tr a rt 3 CΛ Φ CO s: 3 ι-3 Ω a r-ϋ tr β Ό cn M >< o ι-3 CD Cfl Ό ιO O M CΛ td
3 3 β << CD β tr Φ β 3 β tr Φ tr O P- tr Φ CO tr β P- φ li tr Cfl β CD hj P- CD β CD rt Ω a cn hi φ a P- Ό tr P- rt Φ 3 X3 0 φ o Ω Λ CD ua φ Ω M O M Ω cQ CD Ω
P- CD tr li P- P- P- rt M cn Ω CD rt O O β a cn tr β cn CD cn Φ tr 3 β CO rt CD Cfl ti¬
H) o Ω 3 Ω β CD O rt tr M Ω CD rt Ό O Ό O rt 3 φ • P- 3 O H tr ro
0 cn CD X ιQ β 3 tr << CD CO β P- CD tr φ CD tr CD li p- tO CD rt a CD CO Cfl P- hj
CD β cn p- Ω M M Φ 3 CD *» M 3 CO o a CO CD cn -> Φ Ω O • O P- 3 3 ro 3 P-
3 P- 0- 0 rt rt φ a Ω li rt P- O li rt ? β Ω β a CD tQ o cn rt Ό Φ 3 tr β Ml Φ Φ 01 β 3 P- P- P- rt φ CD O rt 3 tr CD ro rt 3 rt M
CD tr - Ό φ H tr Ό P- Cfl β li cQ β Ω 3 tr 3 0 i P- O Ω CD Hi Hi a 0 0 tr o o Φ Φ hi 3 •*% 3 Ω Φ 3 a φ 3 *< CD rt rt Φ ιQ Ω 0 CD hi 3 O
CO M Cfl CD β Ω φ Φ tr Cfl CD P- CD O CD Ω hi CD rt • P- P- rt β Ω ^ β φ Ό 3 β P- CO o CD Cfl Ω 3 CD tr Ω O 3 3 rt O 3 P- a M CO Ω CD σ 3
Ω tr 0- M 3 rt β a β Φ CD φ M ^ P- P- o 3 P- tr •*« ιQ Ω Ω Q rt hj • tr 3 o o cn rt CD hi a Ω CO Cfl a rt a a a β O β Φ Φ Φ M CD O tr o o
CD li 3 β rt hi O P- tr CO P- CO li ** β hi 3 3 CD 3 3 CO CD ^ CO 3 CO CO o • Hi
CD 3 P- p- hi tr rt o rt CD Φ β o CD Ω P- 3 φ 1 Ω Ω rt a β ro tr *
CO 3 Ω CD Cfl φ Φ P- hi P- CD hj . 3 Ω cQ Ό M φ β O CD Ω Ω P- Φ Φ Ω • rt φ β 3 Cfl o CO *< CD Φ o M 3 β Hi rt 0 CD a li CD Ω tr a σ 3- φ hj CD o Ω P- Hi tO 3 ιQ 3 3 3 rt "< o M M 3 3 ^ O hi O 3 H Λ ro
• Ω li tr 3 0 Ω CD Hi • β CD Hi Ω Hi O Φ rt M P- Ω CD CD CD > cQ rt P- hi O CD rt 3 o Cfl σ Ό CO O CD CD β CD σ Ω Ω O CO M tit? o a CD CD CD 3 β 3 O P- hj 3 rt Φ tr CO hj 3 li rt H rt p- Φ CD CD 3 rt ro M 3
& CO tr 3 CD 0 P- P- tr φ hi 3 3 3 CD β ro O Cfl UO ro
Hi Ω o β Cfl o CO 3 rt O ιO vQ Hi CO β CD rt o ^ CD CD P- β a Ω rt • Cfl CO H
CD O hj φ O β Hi rt O tr hi 3 β to Ό 3 CO li 3 3 Ω 3 CO tr P- uq Φ M P- rt 3 o o P- CD H Φ CD O Φ hj Φ tr o CD CD a rt ιQ φ Φ φ a hh • ^ Cfl — •- Ω rt rt cn β α rt CD 3 Φ Ω 5 CO rt a CD a CD iQ rt 3 a rt CD β CD
• hi β n P- CD Ω O CD P- rt P- tr rt P- Φ Φ 3 β O β tr CD rt cn 3 Ω 3
O M β t Cfl Φ < tr a 3- β φ CD φ tr 3 3 0 li 3 O P- O CD 3 ^ O o tr
CD M H. CD 3 M P- CO Φ o cn • 3 H CO •<; P- CD 3 φ CD 3 3 φ 3 a ><: M CΛ
Ω β φ 3 hi < 3 o a K 3 P- CD M Ό a a o Hi CD CD 0) o
P- rt hi tr sQ 3 Φ CD n. CO o rt li hi rt 3 a β tio P- M M CD Cfl fl o a tr P- o "< 3 M Φ tr 1 3 P- β fi tr o β tr 3 β < CD ^ P- rt o cn P- φ Ω 3 a CD Φ 3 Φ 3 a 3 M φ Φ rt Q ii Φ CD 0 ro 3 P- CO 3 rt P- Φ ro φ
Ό P- hi 3 rt φ CD Hi tr Φ Φ 3 Ω hj X a a CD o ^ M O • rt
0 Ό CD CD o 3 tr P- CD 3 < M CD Ω cn Φ 3 • CO tr rt n β rt 3 M ^* ^ iQ ^
M tπ Ω x Φ CD O a rt P- M ct O o o o M P- li •^ CD tr a φ CD •
<: P- P- li rt 3 a P- rt •< Φ β Ω Ό β 3 0 3 CD M Φ P- Ω CO O hh iQ o a o a . Ω Φ Φ O CD "* Ό H o tr li P- ii o Ω cn M o Ω P- β rt to o
M Hi li Φ tr 0- a 3 3' O H Ω li 0 Ω β P- hj rt β "< CO li a 3 CD M hi
•<: ** Φ P- Φ H P- Φ hi O Φ 3 a cQ ^« Ω 0 vQ CD Cfl Hi hi β
Ω rt Ω CD Ω rt a 3 CO CO Φ Ό CO Φ CD tr O β CD Ω ^ M Ω Ω CD o tr CD Ω Ό o CD O CO CO P- Φ O CO t 3 3 Ω hj ii 3 P- O tr O CD
M φ 3 P- o li 3 Cfl "^ φ ϋ Hi o CD o P- P- O CD Ω P- a CO s- CO Ω a rt rt β 3 0 CO 0 rt Hi rt CD Ω hj n CD Φ Ω • β ro CD Φ tiφ Ω tr CD Ω tr 3" tr Ω rt 3 CD Ό 3 Φ hj 3 3 CO Ω j 3 ro O β Φ Ω CO CD Φ φ cn CD P- M tr a 3 CD Ω •ts O CD CD ^ l t a hj rt M o f 3 rt 3 CD O r O P- O P- rt o o cn φ CD Hi Ω M O CO P-
Φ rt Φ 3 P- CD Ω CD M β Cfl cn 3 hi rt Φ 3 3 tiT3 P- Ω CD P- Ω β o hi β 3 •O β tr a β 3 σ M Ό iQ li P- Ό ro rt 3 Ω a O CO M Φ Ω
CO j Ό o 3 Φ a M Ω Φ iQ Hi O tr
"* O β O ro O P- CD CO tr M hi 0 φ M β Φ rt Φ li CD Hi o CO ιQ Ω
. 3 β O 3 X li o ro M o t
O 3 Hi a β O O rt ϋ O Φ CD 3 Φ rt tr M • β O li • "
Ω α Φ ≤ Φ β a 3 3 a O β o O Cfl tQ M Φ
CD Φ n a rt Φ rt O P- Cfl • hj 3 β • 0
3 a 0 t β tr Φ Ω
P- 3 φ tr 3
be employed to control the development of foam. Suitable substances having a selective action, such as e.g antibiotics, can be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the culture is usually 20°C to 45°C, and preferably 25°C to 40°C. Culturing is continued until a maximum of the desired product has formed. This target is usually reached within 10 hours to 160 hours.
Methods for the determination of L-amino acids are known from the prior art. The analysis can thus be carried out, for example, as described by Spackmann et al. (Analytical Chemistry, 30, (1958), 1190) by ion exchange chromatography with subsequent ninhydrin derivation, or it can be carried out by reversed phase HPLC, for example as described by Lindroth et al. (Analytical Chemistry (1979) 51: 1167- 1174) .
The process according to the invention is used for fermentative preparation of amino acids.
The present invention is explained in more detail in the following with the aid of embodiment examples.
The following microorganism was deposited as a pure culture on 26th June 2001 at the Deutsche Sammlung fiir Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty:
• Escherichia coli DH5αmcr/pEC-XK99EgpmBalex as DSM 14376.
The isolation of plasmid DNA from Escherichia coli and all techniques of restriction, Klenow and alkaline phosphatase treatment were carried out by the method of Sambrook et al. (Molecular Cloning. A Laboratory Manual (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA) . Methods for transformation of Escherichia coli are also described in this handbook.
The composition of the usual nutrient media, such as LB or TY medium, can also be found in the handbook by Sambrook et al.
Example 1
Preparation of a genomic cosmid gene library from Corynebacterium glutamicum ATCC 13032.
Chromosomal DNA from Corynebacterium glutamicum ATCC 13032 was isolated as described by Tauch et al. (1995, Plasmid 33:168-179) and partly cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, Product Description Sau3AI, Code no. 27-0913-02) . The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product
Description SAP, Code no. 1758250) . The DNA of the cosmid vector SuperCos (Wahl et al. (1987) Proceedings of the National Academy of Sciences USA 84:2160-2164), obtained from Stratagene (La Jolla, USA, Product Description SuperCosl Cosmid Vector Kit, Code no. 251301) was cleaved with the restriction enzyme Xbal (Amersham Pharmcia, Freiburg, Germany, Product Description Xbal, Code no. 27- 0948-02) and likewise dephosphorylated with shrimp alkaline phosphatase.
The cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany Product Description BamHI, Code no. 27-0868-04) . The cosmid DNA treated in this manner was mixed with the treated ATCC13032 DNA and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA-
Ligase, Code no. 27-0870-04) . The ligation mixture was then packed in phages with the aid of Gigapack II XL Packing Extract (Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217) .
For infection of the E. coli strain NM554 (Raleigh et al . 1988, Nucleic Acid Research 16:1563-1575) the cells were taken up in 10 mM MgS04 and mixed with an aliquot of the phage suspension. The infection and titering of the cosmid library were carried out as described by Sambrook et al . (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor) , the cells being plated out on LB agar (Lennox, 1955, Virology, 1:190) with 100 mg/1 ampicillin. After incubation overnight at 37°C, recombinant individual clones were selected.
Example 2
Isolation and sequencing of the gpmB gene.
The cosmid DNA of an individual colony was isolated with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and partly cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, Product Description Sau3AI, Product No. 27-0913-02) . The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product Description SAP, Product No. 1758250) . After separation by gel electrophoresis, the cosmid fragments in the size range of 1500 to 2000 bp were isolated with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany) .
The DNA of the sequencing vector pZero-1, obtained from Invitrogen (Groningen, Holland, Product Description Zero Background Cloning Kit, Product No. K2500-01) , was cleaved with the restriction enzy BamHI (Amersham Pharmacia, Freiburg, Germany, Product Description BamHI, Product No. 27-0868-04) . The ligation of the cosmid fragments in the sequencing vector pZero-1 was carried out as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor) , the DNA mixture being incubated overnight with T4 ligase (Pharmacia Biotech, Freiburg, Germany) . This ligation mixture was then electroporated (Tauch et al. 1994, FEMS Microbiol Letters, 123:343-7) into the E. coli strain DH5 MCR (Grant, 1990, Proceedings of the National Academy of Sciences U.S.A. 87:4645-4649) and plated out on LB agar (Lennox, 1955, Virology 1:190) with 50 mg/1 zeocin.
The plasmid preparation of the recombinant clones was carried out with the Biorobot 9600 (Product No. 900200, Qiagen, Hilden Germany) . The sequencing was carried out by the dideoxy chain-stopping method of Sanger et al. (1977, Proceedings of the National Academy of Sciences U.S.A.,
74:5463-5467) with modification according to Zimmermann et al. (1990, Nucleic Acids Research, 18:1067). The "RR dRhodamin Terminator Cycle Sequencing Kit" from PE Applied Biosystems (Product No. 403044, Weiterstadt, Germany) was used. The separation by gel electrophoresis and analysis of the sequence reaction were carried out in a "Rotiphoresis NF Acrylamide/Bisacrylamide" Gel (29:1) (Product No. A124.1, Roth, Karlsruhe, Germany) with the "ABI Prism 377" sequencer from PE Applied Biosystems (Weiterstadt, Germany) .
The raw sequence data obtained were then processed using the Staden program package (1986, Nucleic Acids Research, 14:217:231) version 97-0. The individual sequences of the pZerol derivatives were assembled to a continuous contig. The computer-assisted coding region analysis was prepared with the XNIP program (Staden, 1986, Nucleic Acids Research, 14:217-231).
The resulting nucleotide sequence is shown in SEQ ID No. 1. Analysis of the nucleotide sequence showed an open reading frame of 705 base pairs, which was called the gpmB gene. The gpmB gene codes for a protein of 235 amino acids.
Example 3
Preparation of the shuttle expression vector pEC- XK99EgpmBalex for enhancement of the gpmB gene in C. glutamicum
3.1 Cloning of the gpmB gene
From the strain ATCC 13032, chromosomal DNA was isolated by the method of Eikmanns et al. (Microbiology 140: 1817-1828 (1994) ) . On the basis of the sequence of the gpmB gene known for C. glutamicum from example 2, the following oligonucleotides were chosen for the polymerase chain reaction (see SEQ ID No. 3 and SEQ ID No. 4) :
gpmBexl : 5 " ca ggtacc tgg eta cga gga cga tta ag 3 gpmBex2 : 5' tg tctaga aag cat gcg gag gaa tea ac 3"
The primers shown were synthesized by MWG-Biotech AG (Ebersberg, Germany) and the PCR reaction was carried out by the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press) with Pwo-Polymerase from Roche Diagnostics GmbH (Mannheim, Germany) . With the aid of the polymerase chain reaction, the primers allow amplification of a DNA fragment 827 bp in size, which carries the gpmB gene. Furthermore, the primer gpmBexl contains the sequence for the cleavage site of the restriction endonuclease Kpnl, and the primer gpmBex2 the cleavage site of the restriction endonuclease Xbal, which are marked by underlining in the nucleotide sequence shown above.
The gpmB fragment 827 bp in size was cleaved with the restriction endonucleases Kpnl and Xbal and then isolated from the agarose gel with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany) .
3.2 Construction of the shuttle vector pEC-XK99E
The E. coli - C. glutamicum shuttle vector pEC-XK99E was constructed according to the prior art. The vector contains the replication region rep of the plasmid pGAl including the replication effector per (US-A-5, 175, 108; Nesvera et al., Journal of Bacteriology 179, 1525-1532 (1997)), the kanamycin resistance gene aph(3')-Ha from Escherichia coli (Beck et al . (1982), Gene 19: 327-336), the replication origin of the trc promoter, the termination regions Tl and T2, the laclq gene (repressor of the lac operon of E.coli) and a multiple cloning site (mes) (Norrander, J.M. et al . Gene 26, 101-106 (1983)) of the plasmid pTRC99A (Amann et al. (1988), Gene 69: 301-315).
The trc promoter can be induced by addition of the lactose derivative IPTG (isopropyl ?-D-thiogalactopyranoside) .
The E. coli - C. glutamicum shuttle vector pEC-XK99E constructed was transferred into C. glutamicum DSM5715 by means of electroporation (Liebl et al., 1989, FEMS Microbiology Letters, 53:299-303). Selection of the transfor ants took place on LBHIS agar comprising 18.5 g/l brain-heart infusion broth, 0.5 M sorbitol, 5 g/l Bacto- tryptone, 2.5 g/l Bacto-yeast extract, 5 g/l NaCl and 18 g/l Bacto-agar, which had been supplemented with 25 mg/1 kanamycin. Incubation was carried out for 2 days at 33°C.
Plasmid DNA was isolated from a transformant by conventional methods (Peters-Wendisch et al., 1998, Microbiology, 144, 915 - 927), cleaved with the restriction endonuclease Hindlll, and the plasmid was checked by subsequent agarose gel electrophoresis.
The plasmid construct obtained in this way was called pEC- XK99E (figure 1) . The strain obtained by electroporation of CO ro M
O cπ O Cπ O Cπ
IX Φ CD P- ffi *τJ D M rt O < σ M o o Ό li φ ι-3 O CD Φ rt a (-3 CO O Ω _ rt s: rt
^ M 3 3 P- P- M rt • • hi Hi 0 tc P- φ a li ro X r1 ro M 3 tr ro tr • β β σ tr CD tr o Φ a Cfl M CD CD M CD M cπ iQ CO > ro CO CD ro hi ? N P- to Φ CO a M CΛ Φ CO φ uo Ω rt a Ό CO co O 3 Ό • P CD Ω Ό rt 3 3 D << CO Ω CD rt s
M rt t hj ro hj 3 O CO M 3 rt li M CD hj Ό sQ CD M 3 li M Ό β N σ Ω Ό ιΩ hj Ό d 3 ro P- o Hi CD H Ω P- P- p- hj P- M cn . hi O Ό sQ φ O Φ V 3
3, P- φ O P- • Φ hi Φ CD M
Ό O 3 Ω •*« Ό a O o »< 3 CO M tr Ω to Φ II β M CD
3 Ό H rt ^ ≤ hj 3 3 rt CD a rt Cd ro CD ro Ω φ M rt O ti- M to
Cd 3^ P- Q ω D P- 3 P- H ,— . P- CO P- CO « to a O Ω 0 "^ Ω to ro 3
CD O rt o ro O -3 hj rt CD a ) tc tr 0 Φ < O Hi πd Ό •O 3 M rt 3 3 Φ O a P-
M hj O 3 hi P- > Φ tr rt 1 IT1 CD CD 3 Φ 3 M li hj tr 3 P- P- P- O P- hj CO hj tr a
Φ Φ Cfl 3 3 Ω P- O 1 3 rt Ω CD O o H a 3 hi 3 Φ hi 3 Φ σ cn Ω D 51 0 Cπ 0 CD πd CD Ω h3 t? rt ro tO a to 1 sQ CD CD CD CΛ Ό
P- tr CD 3 12 CD 3 o 3 hi hj tr tr ιt- 3 O 3 o 3 β •0 CD s: ro O rt β 3 CΛ S M cn Φ 3 •< p- ω tr li Φ CD 1 ro H a tr φ Ω tr 3 CD o M O " 3 CD Cπ Ω
H • Ω a 3 P- 3 tr ^ Cfl 3 s: α li o rt 3 rt D a CO CD • Ω Hi • CO Ω 3 ι 1 ft W P- P- 3 ιQ CD P- Cfl *« CD 3 CD Ό 3 CD rt rt 3 1 Ω O 3 M X
P_ o P- Ό cn CD \ rt 3 "% cn J tr H β P- α (D Ω Ό tO X iQ tr M M Cπ «
P- tr rt M 3 li O 3 M Ω tO H 1 CD O Ω 3 5D ro CO tr M M M ^ Ό . M β \ uo O ro tr Φ ro M rt tr O 3 rt tr" 3 1 M Φ Ό CO ro CD Φ ro β uo 3 φ Φ 3 Ό uo
Φ CD CD Ό CD ?r Ω X ii P- X φ a Ό Ω M CD rt uo dd P- Ω tO ta M cn j <i Ω ti¬ P- CD O Φ Hi CD tQ a P CD hi hj ,—. < O CD . P. tQ rt Ω tr Φ Ό φ Ω ! ro 3 3 3 M O 3 CD tr o to tr O P- 50 CD Φ • 3 P- *<< P- Hi 1 P- o O M a O P- a a CD M hi -2 cn CO D o φ • !x! Ό O 3 a NO P- 3 O β: X 3 s: d CD hj rt P- 3 tr" O a > Hi φ ii H CO rt Ω a Ω Ω 3 li «
3 M n s: a Hi <! >< Cd O 3 3 P- tr Ω ≤ β rt Φ o rt rt 3 P- CD ,—, hi P- 0 ≤ Ω hj CD CD « φ 00 0 ro rt o CD 3 tr hi O S o tr p- P- P- rt 3 TJ o a P- CD CD si M 3 O Ω 3 Ό CD M 3 tr 3 CO φ 3 Hi P- M Φ
3 3 a tr O li 3 3 u3 O CD o φ o P- a 3 3 -J D ro T3 O CD ? iQ φ O CD • CD cn 3 a a CD Cfl CΛ p- 3 M β tr M 3 S ii CD Ω
Hi tr rt a CD M hi 3 tr P- Φ ** ti¬ tr > CD φ CO β • •< P- o 3
P- Ό •< tr s: d > CD P- 3 P- er CD o Ό m to a rf- φ rt — - Ω o a tO. M Φ P- Ω rt Ω Hi . — . a 3 iQ 3 3 ^ Φ 3 Hi * 3 Φ ro a rt Ω hj ii tQ d CD CO rt rt hj M tiIT" Φ tO • o hj a P- o Ό M M O P- O cQ a M hi CO d hj CD o ro Φ rt rt Φ tr Td 3 TJ cn tr ^ CD Φ M 3 O CD ro β
Φ 3 tr Φ s 3 3 hi 3 tr O tr N> P- CD X O hj rt o CO P- hi 3 Ό rt
P- O O rt o Cfl Φ 3 << 3 Φ -J σ rt tr ta Cfl o P- CO s: <! 1 CD iQ P- o CD t-O a ro rt tr . Hi CD P- O Ό 1 d Ω CD P- a Ω Ό P- rt Φ Ω Ω CD CD CO 3
Λ H φ O 3 X Ό D hi M o H tr H CD N β CO tr rt tr Ω • Ω 3 3 P- P- s; d P- M li £ Ω M O CD • 00 iQ 3 ro Ω o tr Φ rt O P- φ rt Ω
CD ro Ω 3 -J 3 φ d CD •*» Ω -J s: s: a rt cn hj 0 tO li Cfl 3 Φ β
CO 3 rt CD M CD hi σ M rt rt Ω o CD CD a 3 *< rt <i hj M a 3 a 3 rt P- 3 o 3 Φ CD O P- P- O 1 o ω CO o Φ 2! tr M tr ro β CD CO β
Ω O d n rt rt Cπ 3 CΛ Ω M o φ M CO O tc CD ro Ω o rt 3 3 CD CO
CD (D 3 Hi CO P- Cn cQ > CD P- **. li rt 3 Φ Ω • ti¬ rt M CD Ω CD a to rt
M tO CD Z Φ 0 M — ' 3 li P- D hi ro hj O Ω 3 Φ 3 li
M CD Φ Ω !θ P- M 3 O • cn • CD ro <i P- M r H 1 P- a N α C o σ* -J s a o D
Φ j 3 rt P- rt ro < d CD rt 3 CD φ r CD to > X Ω s; φ CΛ p- a o N d CD r o o P- rt CΛ Ό ii m • ti¬ a a Φ cπ 3 s; rt « β P- Ω M s 3
Cfl ^ hi iQ ti¬ <J li Φ Ό CD tr " ro a 00 3 P- hi D o 3 rt φ M M
Ό φ 3 Φ Φ rt ro Φ 0 rt M H P- φ a ≤ 33 N) tr rt P- S o tr M ?r O D
M φ li 3 tr a h M tr Φ O 3 <V P- P- P- cπ ro tr Ω > t? CO M β Ji. to
O tO CO - φ 3 O Φ Ω CD hi s rt rt 3 o P- rt tr rt M cπ S
1 φ CO P- iQ rt Ω o P- tr tr — 3 co P- O β tr rt Cπ π
M > P- tr a rt tr o Hi rt φ β 1 tr tr 0 d tr rt ti¬ ii 3 rt hi CD M D ti¬ 3 0 tr er p- M ro rt Cn H rt ι-3 Φ ro i Φ 3
Example 4
Transformation of the strain DSM5715 with the plasmid pEC- XK99EgpmBalex
The strain DSM5715 was transformed with the plasmid pEC- XK99EgpmBalex using the electroporation method described by Liebl et al., (FEMS Microbiology Letters, 53:299-303 (1989) ) . Selection of the transformants took place on LBHIS agar comprising 18.5 g/l brain-heart infusion broth, 0.5 M sorbitol, 5 g/l Bacto-tryptone, 2.5 g/l Bacto-yeast extract, 5 g/l NaCl and 18 g/l Bacto-agar, which had been supplemented with 25 mg/1 kanamycin. Incubation was carried out for 2 days at 33°C.
Plasmid DNA was isolated from a transformant by conventional methods (Peters-Wendisch et al., 1998, Microbiology, 144, 915 - 927), cleaved with the restriction endonucleases Xbal and Kpnl, and the plasmid was checked by subsequent agarose gel electrophoresis. The strain obtained was called DSM5715/pEC-XK99EgpmBalex.
Example 5
Preparation of Lysine
The C. glutamicum strain DSM5715/pEC-XK99EgpmBalex obtained in example 4 was cultured in a nutrient medium suitable for the production of lysine and the lysine content in the culture supernatant was determined.
For this, the strain was first incubated on an agar plate with the corresponding antibiotic (brain-heart agar with kanamycin (25 mg/1)) for 24 hours at 33°C. Starting from this agar plate culture, a preculture was seeded (10 ml medium in a 100 ml conical flask) . The complete medium Cglll was used as the medium for the preculture. Medium Cg III
NaCl 2.5 g/l
Bacto-Peptone 10 g/l
Bacto-Yeast extract 10 g/l
Glucose (autoclaved separately) 2% (w/v)
The pH was brought to pH 7.4
Kanamycin (25 mg/1) was added to this. The preculture was incubated for 16 hours at 33°C at 240 rpm on a shaking machine. A main culture was seeded from this preculture such that the initial OD (660nm) of the main culture was 0.1. Medium MM was used for the main culture.
Medium MM
CSL (corn steep liquor) 5 g/l
MOPS (morpholinopropanesulfonic acid) 20 g/l
Glucose (autoclaved separately) 50 g/l
(NH4)2S04 25 g/l
KH2P04 0.1 g/l
MgS04 * 7 H20 1.0 g/l
CaCl2 * 2 H20 10 mg/1
FeS04 * 7 H20 10 mg/1
MnS04 * H20 5.0mg/l
Biotin (sterile-filtered) 0.3 mg/1
Thia ine * HCl (sterile-filtered) 0.2 mg/1
L-Leucine (sterile-filtered) 0.1 g/l
CaC03 25 g/l
The CSL, MOPS and the salt solution were brought to pH 7 with aqueous ammonia and autoclaved. The sterile substrate and vitamin solutions were then added, as well as the CaC03 autoclaved in the dry state.
Culturing is carried out in a 10 ml volume in a 100 ml conical flask with baffles. Kanamycin (25 mg/1) and IPTG (lmM/1) was added. Culturing was carried out at 33°C and 80% atmospheric humidity.
After 48 hours, the OD was determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Munich) . The amount of lysine formed was determined with an amino acid analyzer from Eppendorf- BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivation with ninhydrin detection.
The result of the experiment is shown in table 1.
Table 1
Figure imgf000029_0001
Brief Description of the Figures:
Figure 1: Map of the plasmid pEC-XK99E
Figure 2: Map of the plasmid pEC-XK99EgpmBalex
The abbreviations and designations used have the following meaning:
Kan: Kanamycin resistance gene aph(3,)-IIa from Escherichia coli
Hindlll Cleavage site of the restriction enzyme Hindlll
Xbal Cleavage site of the restriction enzyme Xbal
Kpnl Cleavage site of the restriction enzyme Kpnl
Ptrc trc promoter
TI Termination region TI
T2 Termination region T2 per Replication effector per rep Replication region rep of the plasmid pGAl laclq laclq repressor of the lac operon of
Escherichia coli gpmB Cloned gpmB gene

Claims

What is claimed is :
1. Isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence which codes for the gpmB gene, chosen from the group consisting of
a) polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2,
b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70% to the amino acid sequence of SEQ ID No. 2,
c) polynucleotide which is complementary to the polynucleotides of a) or b) , and
d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a) , b) or c) ,
the polypeptide preferably having the activity of phosphoglycerate mutase II.
2. Polynucleotide according to claim 1, wherein the polynucleotide is a preferably recombinant DNA which is capable of replication in coryneform bacteria.
3. Polynucleotide according to claim 1, wherein the polynucleotide is an RNA.
4. Polynucleotide according to claim 2, comprising the nucleic acid sequence as shown in SEQ ID No. 1.
5. DNA according to claim 2 which is capable of replication, comprising (i) the nucleotide sequence shown in SEQ ID No. 1, or
(ii) at least one sequence which corresponds to sequence (i) within the range of the degeneration of the genetic code, or
(iii) at least one sequence which hybridizes with the sequence complementary to sequence (i) or (ii) , and optionally
(iv) sense mutations of neutral function in (i) .
6. DNA according to claim 5 which is capable of replication, wherein the hybridization of sequence (iii) is carried out under a stringency corresponding to at most 2x SSC.
7. Polynucleotide sequence according to claim 2, which codes for a polypeptide which comprises the amino acid sequence shown in SEQ ID No. 2.
8. Coryneform bacteria in which the gpmB gene is enhanced, in particular over-expressed.
9. Escherichia coli strain DH5αmcr/pEC-XK99EgpmBalex as DSM 14376 deposited at the Deutsche Sammlung fur
Mikroorganismen und Zellkulturen [German Collection of Microorganisms and Cell Cultures] , DSMZ, Braunschweig, Germany.
10. Process for the fermentative preparation of L-amino acids, in particular L-lysine, wherein the following steps are carried out:
a) fermentation of the coryneform bacteria which produce the desired L-amino acid and in which at least the gpmB gene or nucleotide sequences which code for it are enhanced, in particular over- expressed, b) concentration of the L-amino acid in the medium or in the cells of the bacteria, and
c) isolation of the L-amino acid.
11. Process according to claim 10, wherein bacteria in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced are employed.
12. Process according to claim 10, wherein bacteria in which the metabolic pathway which reduce the formation of the desired L-amino acid are at least partly eliminated are employed.
13. Process according to claim 10, wherein a strain transformed with a plasmid vector is employed, and the plasmid vector carries the nucleotide sequence which codes for the gpmB gene.
14. Process according to claim 10, wherein the expression of the polynucleotide (s) which code(s) for the gpmB gene is enhanced, in particular over-expressed.
15. Process according to claim 10, wherein the catalytic properties of the polypeptide (enzyme protein) for which the polynucleotide gpmB codes are increased.
16. Process according to claim 10, wherein for the preparation of L-amino acids, coryneform microorganisms in which at the same time one or more of the genes chosen from the group consisting of
16.1 the dapA gene which codes for dihydrodipicolinate synthase,
16.2 the gap gene which codes for glyceraldehyde 3- phosphate dehydrogenase,
16.3 the tpi gene which codes for triose phosphate isomerase,
16.4 the pgk gene which codes for 3-phosphoglycerate kinase,
16.5 the zwf gene which codes for glucose 6- phosphate dehydrogenase,
16.6 the pyc gene which codes for pyruvate carboxylase,
16.7 the mqo gene which codes for malate-quinone oxidoreductase,
16.8 the lysC gene which codes for a feed-back resistant aspartate kinase,
16.9 the lysE gene which codes for lysine export,
16.10 the horn gene which codes for ho oserine dehydrogenase
16.11 the ilvA gene which codes for threonine dehydratase or the ilvA(Fbr) allele which codes for a feed back resistant threonine dehydratase,
16.12 the ilvBN gene which codes for acetohydroxy- acid synthase
16.13 the ilvD gene which codes for dihydroxy-acid dehydratase,
16.14 the zwal gene which codes for the Zwal protein,
is or are enhanced or over-expressed are fermented.
17. Process according to claim 10, wherein for the preparation of L-amino acids, coryneform microorganisms in which at the same time one or more of the genes chosen from the group consisting of,
17.1 the pck gene which codes for phosphoenol pyruvate carboxykinase,
17.2 the pgi gene which codes for glucose 6- phosphate isomerase,
17.3 the poxB gene which codes for pyruvate oxidase,
17.4 the zwa2 gene which codes for the Zwa2 protein,
is or are attenuated are fermented.
18. Coryneform bacteria which contain a vector which carries a polynucleotide according to claim 1.
19. Process according to one or more of claims 10-17, wherein microorganisms of the species Corynebacterium glutamicum are employed.
20. Process according to claim 19, wherein the Corynebacterium glutamicum strain DH5αmcr/pEC-XK99EgpmBalex is employed.
21. Process for discovering RNA, cDNA and DNA in order to isolate nucleic acids, or polynucleotides or genes which code for phosphoglycerate mutase II or have a high similarity with the sequence of the gpmB gene, wherein the polynucleotide comprising the polynucleotide sequences according to claim 1,2,3 or 4 is employed as hybridization probes.
22. Process according to claim 21, wherein arrays, micro arrays or DNA chips are employed.
PCT/EP2001/009453 2000-09-09 2001-08-16 Nucleotide sequences which code for the gpmb gene WO2002020573A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001295470A AU2001295470A1 (en) 2000-09-09 2001-08-16 Nucleotide sequences which code for the gpmb gene
EP01976088A EP1315825A2 (en) 2000-09-09 2001-08-16 Nucleotide sequences which code for the gpmb gene

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10044772 2000-09-09
DE10044772.4 2000-09-09
DE10133668A DE10133668A1 (en) 2000-09-09 2001-07-11 Nucleotide sequences encoding the gpmB gene
DE10133668.3 2001-07-11

Publications (2)

Publication Number Publication Date
WO2002020573A2 true WO2002020573A2 (en) 2002-03-14
WO2002020573A3 WO2002020573A3 (en) 2002-05-16

Family

ID=26007003

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009453 WO2002020573A2 (en) 2000-09-09 2001-08-16 Nucleotide sequences which code for the gpmb gene

Country Status (4)

Country Link
US (1) US20020052486A1 (en)
EP (1) EP1315825A2 (en)
AU (1) AU2001295470A1 (en)
WO (1) WO2002020573A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387527A1 (en) * 1989-03-14 1990-09-19 Degussa Aktiengesellschaft Process for the fermentative production of L-lysine
DE19929365A1 (en) * 1999-06-25 2000-12-28 Basf Lynx Bioscience Ag New genes from Corynebacterium glutamicum, useful for modifying cells for production of primary or secondary metabolites, e.g. amino or fatty acids
WO2001000843A2 (en) * 1999-06-25 2001-01-04 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding metabolic pathway proteins
EP1106693A1 (en) * 1999-12-09 2001-06-13 Degussa AG Nucleotide sequence encoding the zwa2 protein
EP1108790A2 (en) * 1999-12-16 2001-06-20 Kyowa Hakko Kogyo Co., Ltd. Novel polynucleotides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387527A1 (en) * 1989-03-14 1990-09-19 Degussa Aktiengesellschaft Process for the fermentative production of L-lysine
DE19929365A1 (en) * 1999-06-25 2000-12-28 Basf Lynx Bioscience Ag New genes from Corynebacterium glutamicum, useful for modifying cells for production of primary or secondary metabolites, e.g. amino or fatty acids
WO2001000843A2 (en) * 1999-06-25 2001-01-04 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding metabolic pathway proteins
EP1106693A1 (en) * 1999-12-09 2001-06-13 Degussa AG Nucleotide sequence encoding the zwa2 protein
EP1108790A2 (en) * 1999-12-16 2001-06-20 Kyowa Hakko Kogyo Co., Ltd. Novel polynucleotides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EIKMANNS B J ET AL: "MOLECULAR ASPECTS OF LYSINE, THREONINE, AND ISOLEUCINE BIOSYNTHESIS IN CORYNEBACTERIUM GLUTAMICUM" ANTONIE VAN LEEUWENHOEK, DORDRECHT, NL, vol. 64, no. 2, 1993, pages 145-163, XP000918559 *
KRAMER R: "Genetic and physiological approaches for the production of amino acids" JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 45, no. 1, 12 February 1996 (1996-02-12), pages 1-21, XP004036833 ISSN: 0168-1656 *

Also Published As

Publication number Publication date
WO2002020573A3 (en) 2002-05-16
AU2001295470A1 (en) 2002-03-22
EP1315825A2 (en) 2003-06-04
US20020052486A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
EP1315745B1 (en) Recombinant coryneform bacteria overexpressing the glyceraldehyde-3-phosphate dehydrogenase -2 gene , and their use in l-lysine production
US20020055152A1 (en) Nucleotide sequences which code for the 11dD2 gene
US6916636B2 (en) Nucleotide sequences which code for the oxyR gene
EP1317549B1 (en) Isolation and sequencing of the ptsi gene of c. glutamicum
US20050221450A1 (en) Methods of making L-amino acids in coryneform bacteria using the sigE gene
US6777206B2 (en) Nucleotide sequences which code for the RodA protein
US20020106760A1 (en) Nucleotide sequences which code for the dps gene
EP1217069A2 (en) Nucleotide sequences which code for the ilvE gene
US6727086B2 (en) Nucleotide sequences which code for the sigH gene
WO2002024915A1 (en) Dcta (c4-dicarboxylate transporter) from corynebacterium glutamicum
US20020115159A1 (en) Nucleotide sequences coding for the ATR61protein
WO2002022670A1 (en) Nucleotide sequences coding for the ftsx gene
US20020115160A1 (en) Nucleotide sequences which code for the truB gene
US20020086374A1 (en) Nucleotide sequences which code for the dep67 gene
EP1319077A2 (en) Nucleotide sequences which code for the tmk gene
EP1315825A2 (en) Nucleotide sequences which code for the gpmb gene
WO2002018589A2 (en) Nucleotide sequence coding for the sigc gene of corynebacterium glutamicum
US20020090685A1 (en) Nucleotide sequences coding for the ndkA gene
US20020106755A1 (en) Nucleotide sequences coding for the sigM gene
WO2002042466A2 (en) Nucleotide sequences coding for the cysq gene
WO2002024919A1 (en) Nucleotide sequences coding for the thya gene
EP1311683B1 (en) Nucleotide sequences which code for the csta gene from corynebacterium glutamicum
WO2002022632A2 (en) Nucleotide sequences coding for the pknd gene
WO2002034775A2 (en) Nucleotide sequences encoding the hemd and hemb genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001976088

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001976088

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001976088

Country of ref document: EP